Welcome to LookChem.com Sign In|Join Free

CAS

  • or
4-[2-(n-butylsulfonylamino)-2-(methoxy-carbonyl)-ethyl]-aniline is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

160132-37-6

Post Buying Request

160132-37-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

160132-37-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 160132-37-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,0,1,3 and 2 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 160132-37:
(8*1)+(7*6)+(6*0)+(5*1)+(4*3)+(3*2)+(2*3)+(1*7)=86
86 % 10 = 6
So 160132-37-6 is a valid CAS Registry Number.

160132-37-6Downstream Products

160132-37-6Relevant articles and documents

Cyclic urea derivatives, pharmaceutical compositions containing these compounds and processes for preparing them

-

, (2008/06/13)

The invention relates to cyclic urea derivatives of general formula I STR1 wherein Ra, Rb, X and Y are defined as in claim 1, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably aggregation inhibiting effects, and to drugs containing the compounds and processes for preparing them.

CARBOXYLIC ACID COMPOUND HAVING CONDENSED RING, SALT THEREOF AND PHARMACEUTICAL USE THEREOF

-

, (2008/06/13)

A novel carboxylic acid compound having a condensed ring, which is represented by the formula (I) wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, a pharmaceutical composition thereof and pharmaceutical use thereof. The novel carboxylic acid compound having a condensed ring and pharmacologically acceptable salt thereof of the present invention have superior GPIIb/IIIa antagonism in mammals inclusive of human; can be administered orally; have long life in blood and low toxicity; and show less side-effects. Accordingly, they are extremely useful for the prophylaxis and treatment of thrombotic diseases and other diseases

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 160132-37-6